{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:18:30Z","timestamp":1788319110397,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.7759\/cureus.115620","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:03:00Z","timestamp":1788318180000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the Efficacy and Tolerability of Bedaquiline in Drug-Resistant Tuberculosis"],"prefix":"10.7759","author":[{"given":"Hitesha H","family":"Trivedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mittal C","family":"Balat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohmed Sohel","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Tuberculosis. (2026). Accessed. August 20, 2023: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00361-2021","article-title":"New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization","volume":"57","author":"Viney K","year":"2021","unstructured":"Viney K, Linh NN, Gegia M, et al.. New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization. Eur Respir J. 2021, 57:2100361. 10.1183\/13993003.00361-2021","journal-title":"Eur Respir J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie F","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, et al.. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020, 382:893-902. 10.1056\/NEJMoa1901814","journal-title":"N Engl J Med"},{"key":"ref4","unstructured":"WHO consolidated guidelines on drug-resistant tuberculosis treatment. (2019). Accessed. August 20, 2023: https:\/\/www.who.int\/publications\/i\/item\/9789241550529."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06666-8","article-title":"Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"21","author":"Wang MG","year":"2021","unstructured":"Wang MG, Wu SQ, He JQ. Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2021, 21:970. 10.1186\/s12879-021-06666-8","journal-title":"BMC Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-013-0009-3","article-title":"review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis","volume":"2","author":"Fox GJ","year":"2013","unstructured":"Fox GJ, Menzies D.  review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis. Infect Dis Ther. 2013, 2:123-44. 10.1007\/s40121-013-0009-3","journal-title":"Infect Dis Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2021.02.006","article-title":"Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort","volume":"27","author":"Koirala S","year":"2021","unstructured":"Koirala S, Borisov S, Danila E, et al.. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology. 2021, 27:403-12. 10.1016\/j.pulmoe.2021.02.006","journal-title":"Pulmonology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03026-2020","article-title":"Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea","volume":"57","author":"Kwon YS","year":"2021","unstructured":"Kwon YS, Jeon D, Kang H, Yim JJ, Shim TS. Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea. Eur Respir J. 2021, 57:2003026. 10.1183\/13993003.03026-2020","journal-title":"Eur Respir J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00396-9","article-title":"Interim effectiveness and safety comparison of bedaquiline-containing regimens for treatment of diabetic versus non-diabetic MDR\/XDR-TB patients in China: a multicenter retrospective cohort study","volume":"10","author":"Shi L","year":"2021","unstructured":"Shi L, Gao J, Gao M, et al.. Interim effectiveness and safety comparison of bedaquiline-containing regimens for treatment of diabetic versus non-diabetic MDR\/XDR-TB patients in China: a multicenter retrospective cohort study. Infect Dis Ther. 2021, 10:457-70. 10.1007\/s40121-021-00396-9","journal-title":"Infect Dis Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.06.004","article-title":"Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study","volume":"27","author":"Gao M","year":"2021","unstructured":"Gao M, Gao J, Xie L, et al.. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect. 2021, 27:597-602. 10.1016\/j.cmi.2020.06.004","journal-title":"Clin Microbiol Infect"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06126-11","article-title":"Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance","volume":"56","author":"Diacon AH","year":"2012","unstructured":"Diacon AH, Donald PR, Pym A, et al.. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012, 56:3271-6. 10.1128\/AAC.06126-11","journal-title":"Antimicrob Agents Chemother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12091389","article-title":"The efficacy and safety of bedaquiline in the treatment of pulmonary tuberculosis patients: a systematic review and meta-analysis","volume":"12","author":"Tong E","year":"2023","unstructured":"Tong E, Wu Q, Chen Y, et al.. The efficacy and safety of bedaquiline in the treatment of pulmonary tuberculosis patients: a systematic review and meta-analysis. Antibiotics (Basel). 2023, 12:1389. 10.3390\/antibiotics12091389","journal-title":"Antibiotics (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac528","article-title":"Bedaquiline, delamanid, linezolid and clofazimine for treatment of pre-extensively drug-resistant tuberculosis","volume":"76","author":"Padmapriyadarsini C","year":"2022","unstructured":"Padmapriyadarsini C, Vohra V, Bhatnagar A, et al.. Bedaquiline, delamanid, linezolid and clofazimine for treatment of pre-extensively drug-resistant tuberculosis. Clin Infect Dis. 2022, 76:938-46. 10.1093\/cid\/ciac528","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ers\/IDSA clinical practice guideline","volume":"200","author":"Nahid P","year":"2019","unstructured":"Nahid P, Mase SR, Migliori GB, et al.. Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ers\/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019, 200:93-142. 10.1164\/rccm.201909-1874ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-026-05016-2","article-title":"Advances in gene transfer technologies: comparing viral and non-viral vectors for therapeutic applications","volume":"16","author":"Halagali P","year":"2026","unstructured":"Halagali P, Seenivasan R, Sreedevi A, et al.. Advances in gene transfer technologies: comparing viral and non-viral vectors for therapeutic applications. 3 Biotech. 2026, 16:381. 10.1007\/s13205-026-05016-2","journal-title":"3 Biotech"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/522083-evaluation-of-the-efficacy-and-tolerability-of-bedaquiline-in-drug-resistant-tuberculosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:03:08Z","timestamp":1788318188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/522083-evaluation-of-the-efficacy-and-tolerability-of-bedaquiline-in-drug-resistant-tuberculosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.115620","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}